Apollomics, Inc. (APLM) Stock

About Apollomics, Inc.

Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements. Its therapeutic pipeline features APL-101 (Vebreltinib), a potent and selective c-Met inhibitor being developed for non-small cell lung cancer and other advanced malignancies. Also in development is APL-102, an orally administered, small molecule multiple tyrosine kinase inhibitor intended for liver, breast, and esophageal cancers. Furthermore, APL-122 is an investigational tumor inhibitor candidate focused on treating cancers within the brain. The organization was formerly known as CBT Pharmaceuticals, Inc. before adopting the name Apollomics, Inc. in January 2019.

Apollomics, Inc. is led by CEO Hung-Wen Chen, employs 13 people, headquartered in US, publicly traded since 2021.

Apollomics, Inc. (APLM) stock trades at $18.76 with a market capitalization of $20.69M. The stock is valued at a price-to-earnings (P/E) ratio of -2.41, price-to-book of -2.40, price-to-sales of 2.36. Over the past 52 weeks the stock has ranged between $3.66 and $42.12, and currently trades 55.5% below its 52-week high.

On profitability, Apollomics, Inc. generates a return on equity (ROE) of 288.40% — well above the market average, a sign of a high-quality business, return on capital employed of -900.00%, an operating margin of -100.00%, a net profit margin of -128.69%.

Official website: www.apollomicsinc.com